CareDx agreed to buy Naveris in a deal valued at up to $260 million, including $160 million upfront and as much as $100 million tied to revenue milestones. The acquisition is designed to expand CareDx’s precision oncology footprint through Naveris’ liquid biopsy test NavDx, which monitors HPV-related cancers by measuring circulating viral DNA fragments. CareDx said NavDx has Medicare coverage and supports longitudinal disease management; the company expects Naveris’ revenue to grow 30% to 40% annually for the next three years. Naveris operates high-complexity clinical laboratories in Massachusetts and North Carolina and reported $34 million in unaudited 2025 revenue. Management emphasized the transaction is a targeted add-on within HPV-mediated oncology workflows rather than a broader move into MRD testing.